The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8,342.00
Bid: 8,342.00
Ask: 8,344.00
Change: -66.00 (-0.78%)
Spread: 2.00 (0.02%)
Open: 8,357.00
High: 8,377.00
Low: 8,270.00
Yest. Close: 8,408.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Regeneron's antibody drug added to UK Recovery trial of COVID treatments

Mon, 14th Sep 2020 12:00

By Kate Kelland

LONDON, Sept 14 (Reuters) - The world's largest randomised
trial of potential medicines for COVID-19 is to add Regeneron's
experimental antiviral antibody cocktail REGN-COV2 to
the drugs it is testing in patients hospitalised with the
disease.

The UK RECOVERY trial, which has been testing a range of
potential COVID-19 treatments since it began in April, will
compare the effects of adding REGN-COV2 - a lab-manufactured
monoclonal antibody - to standard care.

"This is the first drug actually designed for this disease,"
said Martin Landray, a professor of medicine & epidemiology at
Oxford University who is co-leading the trial.

"There are lots of good reasons for thinking this might be
really quite a powerful treatment," he told Reuters in an
interview.

The addition of Regeneron's drug to the RECOVERY trial comes
amid growing hopes that monoclonal antibodies may emerge as
effective ways to treat COVID-19.

Until now, the RECOVERY trial had mostly been studying
whether existing drugs could be re-purposed to tackle the new
disease, and it has already found answers on a number of them.

In June and September, trial results showed that widely used
steroids such as dexamethasone and hydrocortisone were able to
reduce death rates among severely-ill COVID-19 patients

Also in June, RECOVERY trial results showed that the
anti-malarial drug hydroxychloroquine, once touted by U.S.
President Donald Trump as a potential "game changer" in the
pandemic, was of no benefit in treating COVID-19 patients.

Regeneron's REGN-COV2 cocktail, which the company is already
testing in late-stage clinical trials in people, combines one
Regeneron-made antibody and a second antibody isolated from
people who have recovered after being infected with COVID-19.

The combination is designed to bind to the spike protein
used by the new coronavirus to gain access to human cells,
limiting the virus's ability to escape.

Regeneron developed the biological drug before linking up
with Roche to expand its manufacturing capacity in hopes
of meeting global demand, should the medicine prove effective.
Regeneron would handle U.S. sales, with Roche selling the
medicine around the world.

Landray said his team had secured enough supply of the drug
so that up to "several thousand" patients could be given it in
the trial and compared with several thousand controls.

"Given that the second phase (of COVID-19 infections in the
UK) seems to be coming now, it is a really good time to be
starting this," he said.

The United States already has a $450 million deal for the
cocktail in place, under the terms of which Regeneron will sell
it around 70,000 to 300,000 potential treatment doses or 420,000
to 1.3 million prevention doses of REGN-COV2. Data is due later
this month, Regeneron has said.

Alongside Regeneron, Eli Lilly, working with biotech
firm AbCellera, is seen as a leading contender in the antibody
race. In August it started testing whether its antibody can
prevent COVID-19 infections in nursing homes. A separate trial
testing the compound on recently diagnosed COVID patients may
yield initial data in September or shortly after.

GlaxoSmithKline and partner Vir Biotechnology
also began testing an experimental antibody on newly
diagnosed COVID-19 patients late last month.

AstraZeneca is for now testing its antibody-based
cocktail on healthy volunteers for tolerability.
(Reporting by Kate Kelland, additional reporting by Deena
Beasley, John Miller and Ludwig Burger; editing by Susan Fenton)

More News

AstraZeneca's Koselugo gets EU regulatory approval to treat children

AstraZeneca's Koselugo gets EU regulatory approval to treat children

Today 09:01

AstraZeneca given EU approval for use of Koselugo in children

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.

Today 08:25

Dual-antibody drugs effective against COVID-19 variants in animal study

By Dania NadeemJune 21 (Reuters) - COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washington University School of Medicine in S...

21 Jun 21 19:38

UPDATE 2-U.S. directs millions of COVID-19 shots to Latin America, Africa, Asia

(Adds comments from White House spokesperson)By Jeff MasonJune 21 (Reuters) - The White House laid out a plan on Monday to share 55 million U.S. COVID-19 vaccine doses globally, with roughly 75% of the doses allocated to Latin America and the Cari...

21 Jun 21 17:33

FOCUS-GSK to boost spending power of pharma business post break-up

* GSK hopes June 23 investor day will mark turnaround for shares* New pharma-focused GSK will slash dividends, cut debt* Analysts encourage GSK to purchase external drug assets* Executive Luke Miels points to upcoming pipeline trial resultsBy Ludwi...

21 Jun 21 12:01

UPDATE 3-Philippines seals biggest COVID-19 vaccine order yet, for 40 mln Pfizer doses

* Deliveries to begin in late September* Philippines has secured 113 mln doses from vaccine suppliers* Government wants to vaccinate up to 70 million Filipinos (Updates with Israel medical experts arriving to help boost vaccine rollout)MANILA, Jun...

20 Jun 21 16:45

Vietnam receives 500,000 Sinopharm COVID-19 vaccine doses donation from China

HANOI, June 20 (Reuters) - Vietnam has received a shipment of 500,000 Sinopharm vaccine doses donated by China, the health ministry said on Sunday, as the country is ramping up inoculations to battle against a more widespread outbreak.The Southeas...

20 Jun 21 11:39

CORRECTED-UPDATE 2-Philippines seals deal for 40 mln Pfizer/BioNTech COVID-19 doses

(Corrects timetable of delivery in second paragraph)* Deliveries to begin 'after eight weeks starting August'* Philippines has secured 113 mln doses from vaccine suppliers* Government wants to vaccinate up to 70 million FilipinosMANILA, June 20 (Reu...

20 Jun 21 07:48

UPDATE 1-Italy's Draghi urges no vaccine let up, despite confusion

(Adds quotes, background)ROME, June 18 (Reuters) - Prime Minister Mario Draghi urged Italians on Friday to get fully vaccinated against coronavirus, acknowledging that a government decision to ban AstraZeneca doses for people aged over 60 had crea...

18 Jun 21 19:17

UPDATE 2-Italy's Draghi urges no vaccine let up, signals AstraZeneca U-turn

(Adds quotes, background)By Crispian BalmerROME, June 18 (Reuters) - Prime Minister Mario Draghi urged Italians on Friday to get fully vaccinated against coronavirus, acknowledging that a government decision to ban AstraZeneca doses for people age...

18 Jun 21 19:17

Prime Minister Draghi urges Italians to keep up vaccination drive

ROME, June 18 (Reuters) - Prime Minister Mario Draghi urged Italians on Friday to get fully vaccinated against coronavirus, acknowledging that there was confusion after the government banned the AstraZeneca shot to people over the age of 60.Italy'...

18 Jun 21 18:41

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

18 Jun 21 17:04

AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer

June 18 (Reuters) - AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.The company...

18 Jun 21 14:26

UPDATE 1-AstraZeneca says EU loses legal bid for more vaccine supplies by end-June

(Adds detail)BRUSSELS/LONDON, June 18 (Reuters) - AstraZeneca said on Friday the European Union had lost a legal case against the pharmaceutical firm over the supply of COVID-19 vaccines, with a court in Brussels rejecting an EU request for more ...

18 Jun 21 14:06

UPDATE 2-AstraZeneca says EU loses legal bid for more vaccine supplies by end-June

(adds EU lawyer)BRUSSELS/LONDON, June 18 (Reuters) - AstraZeneca said on Friday the European Union had lost a legal case against the pharmaceutical firm over the supply of COVID-19 vaccines, with a court in Brussels rejecting an EU request for mor...

18 Jun 21 14:06

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.